Qingdao Vland Biotech Inc.
Shanghai Stock ExchangeTotal Valuation
Qingdao Vland Biotech Inc. carries a market capitalization of 3.07B, placing it among publicly traded companies globally. Its enterprise value stands at 3.60B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.07B |
| Enterprise Value | 3.60B |
Share Statistics
Qingdao Vland Biotech Inc. currently has 253.03M shares outstanding.
| Shares Outstanding | 253.03M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Qingdao Vland Biotech Inc. trades at a trailing price-to-earnings ratio of 53.15. The price-to-sales ratio is 2.34, and the price-to-book ratio stands at 3.20.
| PE Ratio | 53.15 |
| PS Ratio | 2.34 |
| PB Ratio | 3.20 |
| P/TBV Ratio | 1.94 |
| P/FCF Ratio | 37.88 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Qingdao Vland Biotech Inc. trades at an EV/EBITDA multiple of 24.65 and an EV/FCF ratio of 36.40. The EV/Sales ratio of 2.64 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 24.65 provides insight into valuation relative to core operating earnings.
| EV / Sales | 2.64 |
| EV / EBITDA | 24.65 |
| EV / EBIT | 24.65 |
| EV / FCF | 36.40 |
Financial Position
Qingdao Vland Biotech Inc. maintains a current ratio of 1.02, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 34.33, indicating elevated leverage, while an interest coverage ratio of 7.38 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 1.02 |
| Quick Ratio | 0.34 |
| Debt / Equity | 34.33 |
| Debt / EBITDA | 4.37 |
| Interest Coverage | 7.38 |
Financial Efficiency
Qingdao Vland Biotech Inc. posts a return on equity of 6.14 and a return on invested capital of 4.24.
| Return on Equity (ROE) | 6.14 |
| Return on Assets (ROA) | 2.00 |
| Return on Invested Capital (ROIC) | 4.24 |
| Return on Capital Employed (ROCE) | 2.47 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.44 |
Taxes
Over the trailing twelve months, Qingdao Vland Biotech Inc. has paid 31.57M in income taxes, reflecting an effective tax rate of 26.04.
| Income Tax | 31.57M |
| Effective Tax Rate | 26.04 |
Stock Price Statistics
Qingdao Vland Biotech Inc.'s stock has declined approximately -9.12491% over the past 52 weeks. The 50-day moving average sits at 13.39, while the 200-day moving average is 14.58.
| Beta (5Y) | N/A |
| 52-Week Price Change | -9.12491% |
| 50-Day Moving Average | 13.39 |
| 200-Day Moving Average | 14.58 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Qingdao Vland Biotech Inc. generated 1.36B in revenue and converted that into 60.00M in net income, yielding earnings per share of 0.37. EBITDA reached 145.94M, while operating income came in at 145.94M.
| Revenue | 1.36B |
| Gross Profit | 616.14M |
| Operating Income | 145.94M |
| Pretax Income | 121.24M |
| Net Income | 60.00M |
| EBITDA | 145.94M |
| EBIT | 145.94M |
| Earnings Per Share (EPS) | 0.37 |
Balance Sheet
Qingdao Vland Biotech Inc. holds 350.22M in cash and equivalents against 638.06M in total debt, resulting in a net debt position of 380.56M. Total book value stands at 995.25M, with working capital of 20.69M providing operational flexibility.
| Cash & Cash Equivalents | 350.22M |
| Total Debt | 638.06M |
| Net Debt | 380.56M |
| Equity (Book Value) | 995.25M |
| Book Value Per Share | 4.16 |
| Working Capital | 20.69M |
Cash Flow
After subtracting -84.19M in capital expenditures, free cash flow totaled -84.19M - equivalent to -0.35 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -84.19M |
| Free Cash Flow | -84.19M |
| FCF Per Share | -0.35 |
Margins
Qingdao Vland Biotech Inc. operates with a gross margin of 45.18, reflecting its pricing power and cost economics. The operating margin of 10.70 and net profit margin of 4.40 provide insight into operational efficiency.
| Gross Margin | 45.18 |
| Operating Margin | 10.70 |
| Pretax Margin | 8.89 |
| Profit Margin | 4.40 |
| EBITDA Margin | 10.70 |
Dividends & Yields
The company's payout ratio of 44.69 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.22 |
| Dividend Yield | N/A |
| Payout Ratio | 44.69 |
| Shareholder Yield | 7.46 |
| FCF Yield | 2.64 |
Stock Splits
Qingdao Vland Biotech Inc.'s most recent stock split took place on May 25, 2021 with a 5:7 split ratio.
| Last Split Date | 5/25/2021 |
| Split Ratio | 5:7 |
Scores
Qingdao Vland Biotech Inc. posts an Altman Z-Score of 2.82, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.82 |